Outcomes with erlotinib (Tarceva®) in a Yorkshire cancer centre

被引：0
|
作者：
O'Toole, L. [1 ]
Bond, M. [1 ]
Snee, M. [1 ]
机构：
[1] Cookridge Hosp, Leeds LS16 6QB, W Yorkshire, England
来源：
LUNG CANCER | 2007年 / 57卷
关键词：
D O I：
10.1016/S0169-5002(07)70350-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
24
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [31] Tarceva - Erlotinib - Genentech/Osi pharmaceuticals - Tyrosine kinase inhibitor approved for NSCLC
    不详
    FORMULARY, 2004, 39 (12) : 568 - 568
  • [32] DASATINIB (SPRYCEL) AND ERLOTINIB (TARCEVA) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA: A PHASE 1 TRIAL
    Desjardins, Annick
    Peters, Katherine B.
    Vredenburgh, James J.
    Friedman, Henry S.
    Reardon, David A.
    NEURO-ONCOLOGY, 2010, 12 : 51 - 51
  • [33] Photodynamic therapy (PDT) for lung cancer: the Yorkshire Laser Centre experience
    Moghissi, K.
    Dixon, Kate
    Thorpe, J. A. C.
    Oxtoby, C.
    Stringer, M. R.
    PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2004, 1 (03) : 253 - 262
  • [34] Yorkshire Assembly (Louise Browne Yorkshire Ballet Scholarship Centre)
    不详
    DANCING TIMES, 2008, 98 (1175): : 71 - 71
  • [35] Superior anti-tumor activity of ADH-1 in vivo compared to erlotinib (Tarceva®) in lung cancer cell lines
    Chan, Daniel
    Gupta, Mukur
    Zheng, Di
    Zhang, Zhiyong
    Sui, Xiaomei
    Peters, William
    Bunn, Paul
    CANCER RESEARCH, 2009, 69
  • [36] Tarceva™ (erlotinib) in combination with xeloda and oxaliplatin in patients with metastatic colorectal cancer (CRC) -: A phase I dose escalation trial.
    Van Cutsem, E
    Beale, P
    Delord, JP
    Verslype, C
    Brennscheidt, U
    Feyereislova, A
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6095S - 6096S
  • [37] The use of PET-CT scan in the assessment of response to Tarceva (erlotinib) in non small cell lung (NSCLC) cancer patients
    O'Brien, Mary E.
    Myerson, James S.
    Popat, Sanjay
    Puglisi, Martina
    Starling, Naureen
    Trani, Leonardo
    Bhupinder, Sharma
    Gary, Cook
    Sue, Ashley
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S390 - S391
  • [38] Phase II study of erlotinib (Tarceva, OSI774) in women with recurrent or metastatic endometrial cancer - NCICIND 148.
    Oza, AM
    Elit, L
    Eisenhauer, E
    Hoskins, PJ
    Biagi, J
    Carey, M
    Dubuc-Lissoir, J
    Dundas, G
    Stuart, G
    Matthews, S
    Tsao, M
    Dancey, J
    Fyles, A
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6094S - 6094S
  • [39] A PHASE I TRIAL OF DASATINIB (SPRYCEL) AND ERLOTINIB (TARCEVA) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA
    Reardon, David
    Desjardins, Annick
    Vredenburgh, James
    Friedman, Allan
    Sampson, John
    Gururangan, Sridharan
    Rich, Jeremy
    Friedman, Henry
    NEURO-ONCOLOGY, 2008, 10 (05) : 840 - 840
  • [40] Anti-tumor activity of ADH-1 in vitro and in vivo in combination with erlotinib (Tarceva®) in lung cancer cell lines
    Chan, Daniel C.
    Gupta, Mukur
    Zhang Zhiyong
    Zheng Di
    Sui Xiaomei
    Peters, Williams P.
    Bunn, Paul A., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S795 - S795
12345